1. The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders. Issue 10 (12th August 2020) Authors: Robert, Aude; Pujals, Anaïs; Favre, Loetitia; Debernardi, Justine; Wiels, Joëlle Journal: Molecular oncology Issue: Volume 14:Issue 10(2020) Page Start: 2520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗